Finance

Lists
Why is 002800 up 2.38%?
Dive Deeper
002800:KOSDAQ
Sinsin Pharmaceutical Co Ltd
â‚©4,310.00
+2.38%
(+100.00) 1D
Oct 16, 3:30:26 PM GMT+9  ·   KRW
All symbols
SymbolPriceChange% Change
Generating top insights for 002800...
Open
â‚©4,215
High
â‚©4,310
Low
â‚©4,215
Mkt. cap
65.38B
Avg. vol.
67.84K
Volume
29.53K
Dividend
1.86%
Quarterly dividend
â‚©20
Ex-dividend date
Dec 27, 2024
P/E ratio
4.86
52-wk high
â‚©6,990
52-wk low
â‚©3,900
EPS
â‚©888
Shares outstanding
15.17M
No. of employees
367
Open
â‚©4,215
High
â‚©4,310
Low
â‚©4,215
Mkt. cap
65.38B
Avg. vol.
67.84K
Volume
29.53K
Dividend
1.86%
Quarterly dividend
â‚©20
Ex-dividend date
Dec 27, 2024
P/E ratio
4.86
52-wk high
â‚©6,990
52-wk low
â‚©3,900
EPS
â‚©888
Shares outstanding
15.17M
No. of employees
367
News stories
From web sources and news partners
About Sinsin Pharmaceutical Co Ltd
CEOByoungKi Lee
Employees367
Founded1959
Headquarters-
SectorPharmaceutical industry
Websitesinsin.com
Previous reportsAll values in KRW
Loading Previous Earnings...
Revenue
Net income
All values in KRW
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
30.11B
28.76B
30.18B
34.00B
Cost of goods sold
18.32B
17.51B
18.67B
20.51B
Cost of revenue
18.32B
17.51B
18.67B
20.51B
Research and development expenses
156.94M
275.88M
136.53M
150.93M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
7.36B
7.33B
7.76B
9.05B
Operating expense
7.83B
7.91B
8.33B
9.43B
Total operating expenses
26.16B
25.42B
27.00B
29.93B
Operating income
3.96B
3.34B
3.18B
4.06B
Other non operating income
14.65M
464.34M
23.56M
-57.81M
EBT including unusual items
3.75B
3.65B
3.19B
4.09B
EBT excluding unusual items
3.74B
3.51B
3.19B
3.79B
Income tax expense
347.04M
154.08M
334.12M
446.55M
Effective tax rate
9.26%
4.22%
10.46%
10.91%
Other operating expenses
75.40M
62.30M
163.70M
44.19M
Net income
3.42B
3.50B
2.86B
3.68B
Net profit margin
11.36%
12.16%
9.49%
10.84%
Earnings per share
-
-
-
-
Interest and investment income
6.32M
11.16M
16.65M
18.72M
Interest expense
-390.64M
-370.91M
-340.70M
-325.24M
Net interest expenses
-384.32M
-359.75M
-324.06M
-306.52M
Depreciation and amortization charges
235.18M
230.39M
229.79M
222.35M
EBITDA
4.97B
4.34B
4.20B
5.09B
Gain or loss from assets sale
-12.70M
-
-
-
AI content may include mistakes. Learn more
Google apps